Morristown, NJ, January 3, 2012 - Actavis Group, an international pharmaceuticals company, today announced that it has begun shipping Clobetasol Propionate Shampoo and Clobetasol Propionate Lotion, generic equivalents to Galderma's Clobex® Shampoo and Clobex® Topical Lotion.  Due to Actavis' first-to-file status, the FDA has granted Actavis a 180-day marketing exclusivity. 

Combined annual brand sales of Clobex® Shampoo and Clobex® Topical Lotion totaled $89.9 million for the 12 months ending September 30, 2011, according to IMS Health.   

Commenting on the new approval, Doug Boothe, CEO of Actavis in the US, said:
"The launch of Clobetasol Propionate Shampoo and Clobetasol Propionate Lotion displays our continuing commitment to introduce new, high quality generic products to the marketplace, as well as highlights our expertise in developming and manufacturing a wide range of dosage forms.  Actavis' drive to be a leader in generic pharmaceuticals is supported by one of the largest product development pipelines in the industry."

Inquiries:
David Myers, Jr.
Senior Manager, Products & Communications
Tel: (973) 993-4503
E-mail: dmyers@actavis.us

Clobex® is a registered trademark of a party other than Actavis